Neurocrine Biosciences stock hits all-time high at 176.1 USD
Neurocrine Biosciences Inc. stock has reached an all-time high of 176.1 USD, reflecting a 35.23% increase over the past year and indicating strong investor confidence. The company's market capitalization is now $17.51 billion, with shares trading just 1% below their 52-week high. This achievement coincides with recent positive clinical developments, including a Phase 2 study for crinecerfont and promising long-term data for Crenessity and Vykat.
RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating
RBC Capital has increased its price target for Neurocrine Biosciences (NBIX) to $195, up from the previous $183. The firm has concurrently maintained its Outperform rating on the company's stock. This adjustment reflects RBC Capital's updated outlook on Neurocrine Biosciences.
Reasons Why Investors Should Consider Betting on Neurocrine Stock
Neurocrine Biosciences is presented as a strong investment due to the commercial success of its marketed drugs, Ingrezza and Crenessity, and a robust late-stage neuroscience pipeline with candidates like direclidine and osavampator. The recent acquisition of Soleno Therapeutics, adding Vykat XR for Prader-Willi syndrome, further strengthens its commercial portfolio. The company holds a Zacks Rank #1 (Strong Buy) with increasing EPS estimates for 2026 and 2027.
Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside
Neurocrine Biosciences (NBIX) shows strong growth potential with a 12.47% potential upside based on analyst projections. The company specializes in neurological, psychiatric, endocrine, and immunological disorders, boasting a $17.52 billion market cap, robust revenue growth, and positive analyst sentiment with a target price of $195.99. Strong financials, strategic collaborations, and a promising product pipeline position NBIX as an attractive investment in the biotech sector.
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX
This article provides financial information for Neurocrine Biosciences, Inc. (NASDAQ: NBIX), specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or data placeholder from TradingView, offering a snapshot of financial metrics for the biotechnology company. The content primarily lists navigation and platform features, indicating it's a financial data page rather than a detailed news analysis.
NBIX - Neurocrine Biosciences Inc Options
This article provides a detailed financial overview of Neurocrine Biosciences Inc. (NBIX), including its market performance, valuation metrics, earnings, sales data, and insider/institutional ownership. It also lists key financial ratios and stock performance across various timeframes. The information is presented as of July 2, with the stock closing at $174.26, up 3.87%.
What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders
Neurocrine Biosciences was removed from the Russell 1000 Dynamic Index in late June 2026, despite strong INGREZZA sales and an improved profit outlook. The company's investment narrative continues to center on INGREZZA's commercial performance while the rare disease portfolio scales, with fresh clinical data for CRENESSITY in congenital adrenal hyperplasia adding depth. Analysts project $5.1 billion in revenue and $1.5 billion in earnings by 2029, suggesting a 15% upside to its current price, though concentration risk and reimbursement questions remain.
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX)
Neurocrine Biosciences (NBIX) maintains a Buy rating due to strong performance of its key drugs, Ingrezza and Crenessity, and the rapid uptake of its recently acquired Vykat. The company reported a 44% year-on-year revenue increase in Q1 2026 to $811 million, with high growth expectations reflected in its valuation. Patent protection until 2038 for Ingrezza and a solid financial position support long-term growth and potential pipeline expansions.
Zacks.com featured highlights include Neurocrine Biosciences, MYR Group, Block, Delek US Holdings and Dycom Industries
Zacks.com highlights five stocks – Neurocrine Biosciences, MYR Group, Block, Delek US Holdings, and Dycom Industries – selected for their strong relative price strength and solid fundamentals as the U.S. stock market enters the second half of 2026 on a strong footing. The article explains the "Relative Price Strength Strategy" and provides details on why each company is a compelling investment, including their earnings growth, market performance, and analyst estimates.
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences has launched a Phase 2 clinical study for crinecerfont in pediatric patients aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). This study aims to evaluate the safety and tolerability of the drug in this young population, who currently lack approved therapies and are often exposed to high doses of glucocorticoids. The company anticipates these results will support a supplemental New Drug Application to expand Crinecerfont's approved U.S. indication to include patients under 4 years of age, building on its prior FDA approval for patients aged 4 and older.
What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders
Neurocrine Biosciences was removed from the Russell 1000 Dynamic Index in late June 2026, despite analysts noting strong INGREZZA sales and an improved profit outlook. The company's investment narrative remains centered on INGREZZA's commercial performance as its rare disease portfolio scales, with fresh clinical data for CRENESSITY strengthening its medical case. Despite optimistic analyst forecasts, the index removal and potential reimbursement challenges for CRENESSITY highlight ongoing risks, including product concentration and payer scrutiny, suggesting a need for investors to carefully evaluate the company's financial health and fair value.
Neurocrine (NBIX) Reports Clinically Meaningful Benefits in 94% of Patients Treated for Tardive Dyskinesia
Neurocrine Biosciences (NBIX) presented new data from its KINECT-4 trial, showing that its drug valbenazine (sold as INGREZZA) provided clinically meaningful benefits to 94% of patients with tardive dyskinesia over 48 weeks. This figure includes patients who achieved full remission and those with significant symptom reduction. The company also highlighted a separate analysis revealing that 90% of newly diagnosed Medicare TD patients have at least one liver-related risk factor, reinforcing the need for careful management.
Neurocrine starts phase 2 trial of crinecerfont in infants with CAH
Neurocrine Biosciences Inc. has initiated a Phase 2 clinical study for crinecerfont in infants aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). This study aims to assess the drug's safety, tolerability, and pharmacokinetic/pharmacodynamic effects, with the goal of expanding its FDA approval to this younger age group. Crinecerfont is already approved for patients 4 years and older with CAH, and the company is also conducting a similar study in the EU for children under 2 years old.
Price to book forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX
The article provides information regarding the "Price to book forward" for Neurocrine Biosciences, Inc. (NASDAQ: NBIX). It appears to be a financial data snippet from TradingView, indicating no trades and presenting a financial metric for the company. The content primarily acts as a title for a financial data presentation rather than an in-depth article.
Price to book forward of Neurocrine Biosciences, Inc. – MIL:1NBIX
This article provides financial data, specifically the "Price to book forward," for Neurocrine Biosciences, Inc. (MIL:1NBIX). It notes the current value, change, and percentage change. The content appears to be a stub from a financial data platform, indicating market status and data sources.
Neurocrine (NBIX) legal chief exercises options and sells 10,000 shares
Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 10,000 shares and subsequently sold these shares in open-market transactions. These sales, executed under a pre-arranged Rule 10b5-1 trading plan, converted option value into cash without increasing his net share ownership. Following these transactions, Lippoldt directly holds 54,729 shares of NBIX common stock.
Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says
UBS remains optimistic about Neurocrine Biosciences, reiterating its "Buy" rating and $170 price target. The firm believes the strong performance of Ingrezza will enable Neurocrine to achieve and potentially upgrade its 2026 sales guidance of $2.7 billion. UBS also notes that current valuation appears to discount the company's future growth potential.
9,800-share Form 144 filed for NBIX (NASDAQ: NBIX)
Neurocrine Biosciences Inc. (NASDAQ: NBIX) has filed a Form 144 indicating a proposed sale of 9,800 shares of common stock, stemming from an exercise of stock options on June 29, 2026. The filing also notes a separate 10b5-1 sale of 200 shares on June 26, 2026. Morgan Stanley Smith Barney LLC is listed as the broker for the proposed transaction.
Neurocrine Biosciences stock hits all-time high at 169.62 USD By Investing.com
Neurocrine Biosciences Inc. (NBIX) stock reached an all-time high of $169.62 USD, reflecting a 34.08% increase over the past year. The biotech firm's market performance is supported by a $16.94 billion market cap, 28.6% revenue growth, and a low PEG ratio of 0.21, suggesting undervaluation. Recent positive news includes presentations at the ENDO 2026 conference showcasing long-term data for VYKAT XR and Crenessity, and a reiterated Buy rating from Stifel with a $188.00 price target.
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research has named Neurocrine Biosciences (NBIX) as its Bull of the Day due to its strong earnings growth, successful INGREZZA treatment, expanding commercial portfolio, and promising pipeline. Conversely, Ryanair Holdings (RYAAY) has been designated as the Bear of the Day amidst concerns over weakening pricing trends, rising operating costs, and limited earnings visibility, leading to downward revisions in analyst estimates. The article also provides a separate analysis of Netflix's AI strategy and its competitive landscape, including Amazon and Disney.
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research has named Neurocrine Biosciences as its Bull of the Day due to strong earnings revisions and the success of its drug INGREZZA. Conversely, Ryanair Holdings is designated as the Bear of the Day because of weak summer fare expectations, rising operating costs, and limited management visibility. The article also touches on Netflix's AI strategy and its competitive landscape against Amazon and Disney.
Bull of the Day: Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX) has been designated as the "Bull of the Day" due to its strong earnings growth, impressive commercial execution, and promising pipeline. Analysts have significantly revised upward their EPS estimates for the company, driven by the continued success of its flagship movement-disorder treatment, INGREZZA. Despite recent stock highs, NBIX is considered reasonably valued with a healthy balance sheet and strong projected revenue growth, making it an attractive prospect for investors seeking a profitable biotech company with strong earnings momentum.
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap?
Neurocrine Biosciences (NBIX) recently presented new CRENESSITY data at ENDO 2026, highlighting initial evidence in 11ß hydroxylase deficiency and two-year findings on cardiometabolic, bone, and quality of life. The stock has seen strong momentum with significant returns over the last 90 days and a year, prompting questions about its current valuation. Despite a fair value of $192.88, indicating it is undervalued, the company's future depends on sustained uptake of CRENESSITY and avoiding pricing pressures.
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap?
Neurocrine Biosciences (NBIX) presented new CRENESSITY data at ENDO 2026, showing strong momentum with recent share price gains. Despite a 30.92% 90-day return and a current valuation of US$16.9 billion, Simply Wall St assesses NBIX shares to be undervalued with an intrinsic fair value of $192.88, indicating a potential buying opportunity driven by the strong commercial prospects of CRENESSITY. The analysis cautions that continued CRENESSITY uptake and stable pricing are crucial for this bullish outlook.
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now
Neurocrine Biosciences (NBIX) is highlighted as a high-growth NASDAQ stock, following positive two-year Phase 3 data for their drug CRENESSITY. The data showed significant improvements in pediatric patients with congenital adrenal hyperplasia, including slowed bone age progression and increased predicted adult height, along with high caregiver satisfaction. Despite NBIX's potential, the article suggests that certain AI stocks may offer even higher returns in a shorter timeframe, directing readers to a report on the "cheapest AI stock" with 10,000% upside potential.
Neurocrine Biosciences (NBIX): High Growth Stocks to Buy Right Now
Neurocrine Biosciences (NBIX) is highlighted as a high-growth stock due to promising clinical trial results for its drug CRENESSITY in treating congenital adrenal hyperplasia (CAH). The study showed significant reductions in adrenal hormones and steroid precursors, and allowed many patients to decrease or discontinue other medications. The article suggests that while NBIX has potential, certain AI stocks might offer greater upside.
Neurocrine Biosciences, Inc. Actuals & Estimates (NASDAQ:NBIX)
This article provides an overview of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and analyst estimates for earnings and revenue, along with future projections and key financial metrics like EBITDA. The report highlights that NBIX does not pay dividends and offers information on upcoming earnings reports.
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June By Investing.com
This article announces a Form 144 filing for Neurocrine Biosciences Inc. related to June 26. It highlights the volatile nature of financial markets and cryptocurrencies, reminding investors of the high risks involved. The piece also includes a disclaimer about the accuracy and real-time nature of the data provided by Investing.com.
Price to earnings forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX
This article provides the "Price to earnings forward" value for Neurocrine Biosciences, Inc. (NASDAQ: NBIX). The core content seems to be a single data point related to the stock's financial performance. It also includes various navigational elements and disclaimers from the financial platform, TradingView.
Price to sales forward of Neurocrine Biosciences, Inc. – DUS:NB3
This page from TradingView provides financial information for Neurocrine Biosciences, Inc. (NB3) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or a placeholder, as no specific financial data or analysis is presented beyond the title. It mainly consists of navigation elements and copyright information.
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – DUS:NB3
This article displays the "Enterprise value to EBIT forward" for Neurocrine Biosciences, Inc. (DUS:NB3) on TradingView. It appears to be a financial data point for the company, indicating valuation metrics for investors. The page provides an overview of available financial tools and data on the TradingView platform.
Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
This page provides financial actuals and estimates for Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh (BMFBOVESPA:N1BI34). Users can explore reported financial data and analyst estimates, comparing actual results with various estimates and visualizing trends across income statements, balance sheets, and cash flow statements. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
NBIX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Neurocrine Biosciences, Inc. (NBIX) stock, including its current price, analyst ratings, and future price predictions for 2027. It details the company's financial performance, such as recent earnings and revenue, and provides information on its market capitalization, volatility, and employee count. The report also addresses common investor questions regarding NBIX's stock performance and investment recommendations.
Best Momentum Stocks to Buy for June 24th
This article identifies three momentum stocks with a Zacks Rank #1 for investors to consider: Neurocrine Biosciences, Inc. (NBIX), Industrial Logistics Properties Trust (ILPT), and Casey's General Stores, Inc. (CASY). Each company has demonstrated strong earnings estimate revisions and significant stock price gains over the last three months, outperforming the S&P 500. Investors are encouraged to review these stocks for potential strong performance.
Neurocrine Biosciences Inc (NBIX) Institutional Confidence
Neurocrine Biosciences Inc (NBIX) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional holdings comprise 99.97% of shares, a slight decrease from the previous quarter. The largest institutional shareholder is James Simons, holding 2.40% of outstanding shares.
Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Neurocrine Biosciences Inc (NBIX), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. While technical indicators show mixed signals with some "Sell" and "Neutral" ratings, moving averages predominantly indicate "Buy" signals. The stock is currently trading between a resistance level of $169.32 and a support level of $153.81, suggesting potential for range-bound swing trading.
New Strong Buy Stocks for June 24th
Zacks Investment Research has identified five new "Strong Buy" stocks for June 24th, based on their Zacks Rank #1. These companies—Byline Bancorp, Navigator Holdings, Neurocrine Biosciences, TFI International, and Bunge Global SA—have all seen significant increases in their current year earnings estimates over the past 60 days. Investors can access the complete list of top-ranked stocks and further research on these selections.
What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders
Neurocrine Biosciences recently presented new data at ENDO 2026 for CRENESSITY (crinecerfont), showing strong hormonal control and glucocorticoid-sparing benefits in classic congenital adrenal hyperplasia, including the rarer 11ß-hydroxylase deficiency subtype. This data strengthens CRENESSITY’s profile, particularly with improved cardiometabolic markers, aligning with analyst expectations for it as a key growth driver. While the company projects significant revenue and earnings growth by 2029, investors should consider concerns about pricing pressure and concentration risk stemming from its reliance on just two main products.
What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders
Neurocrine Biosciences reported new data at ENDO 2026 for CRENESSITY (crinecerfont) showing strong hormonal control and glucocorticoid-sparing benefits in classic congenital adrenal hyperplasia, including a rarer subtype. This new evidence for improved cardiometabolic outcomes strengthens NBIX’s investment narrative, particularly concerning CRENESSITY as a growth pillar. However, investors should be aware of concentration risk due to the company's dependence on only two main products.
What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders
Neurocrine Biosciences reported new data for CRENESSITY (crinecerfont) at ENDO 2026, showing strong hormonal control and glucocorticoid-sparing benefits in classic congenital adrenal hyperplasia, including the rarer 11ß-hydroxylase deficiency subtype. This data strengthens CRENESSITY's profile and could influence payer and physician views, adding depth to the investment narrative, although the company still faces concentration risk with only two key products. Analysts project significant revenue and earnings growth by 2029, suggesting a fair value upside for NBIX.
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 22.8% Potential Upside Amid Strong Growth Prospects
Neurocrine Biosciences (NBIX) shows significant growth potential with a 22.8% potential upside as per analyst target price projections, currently trading at $158.29 with a $15.92 billion market capitalization. The company exhibits strong financials, including a 22.50% ROE and $590.55 million in free cash flow, alongside a robust product pipeline and positive analyst sentiment. Its investment in business development over dividends suggests long-term shareholder value enhancement.
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) is currently trading at $158.29, which Simply Wall St considers 18% undervalued compared to a fair value of $192.88, especially after new CRENESSITY data was presented at ENDO 2026. The company shows strong momentum with double-digit revenue and net income growth, a diversified late-stage CNS pipeline, and ongoing internal innovation. Despite the positive outlook, investors are cautioned to consider execution risks like pricing pressure on INGREZZA and reliance on a few key drugs.
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) is currently valued at $158.29, but new CRENESSITY data from ENDO 2026 suggests it could be 18% undervalued with a narrative fair value of $192.88. This valuation is supported by strong revenue and net income growth, a diversified late-stage CNS pipeline, and ongoing innovation in biologics. However, investors should also consider execution risks, including pricing pressure on INGREZZA and a reliance on a few key drugs.
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data
Neurocrine Biosciences (NBIX) stock is considered 18% undervalued by Simply Wall St analysts following new CRENESSITY data presented at ENDO 2026, which showed positive hormone normalization and cardiometabolic/bone health outcomes. Despite a 23.97% 90-day share price return, analysts maintain a fair value of $192.88 against the current $158.29, supported by a diversified CNS pipeline and ongoing innovation. The article also notes potential execution risks, including pricing pressure on INGREZZA and reliance on key drugs, while comparing NBIX's P/E ratio to industry averages.
Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis
Neurocrine Biosciences Inc (NBIX) currently holds a financial score of 8.44, ranking 55 out of 157 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $814.50 million, up 42.25% year-over-year, and a net profit increase of 2405.06% year-over-year. Key financial indicators like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns were also highlighted, generally showing strong performance.
Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Neurocrine Biosciences Inc (NBIX), identifying its major institutional holders and their proportion of shares. It also provides a breakdown of shareholder types and a historical overview of institutional shareholding changes over recent quarters. Additionally, it lists several ETFs that hold NBIX as a proportion of their portfolios.
Neurocrine Biosciences Inc (NBIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Neurocrine Biosciences Inc (NBIX), detailing its business segments. As of April 6, 2024, the company's main revenue streams are INGREZZA ($2.51B, 88.70%) and CRENESSITY ($301.20M, 10.63%), with a small "Other" category. The financial data presented covers various fiscal years and quarters, with the most recent provided for FY2025Q4.
Neurocrine Biosciences Inc (NBIX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Neurocrine Biosciences Inc (NBIX) focusing on its dividend and stock split history. It indicates that NBIX has distributed $0.00 in dividends over the past five years and shows no historical data for stock splits. The piece includes current trading information for NBIX, such as its stock price, market cap, and P/E ratio.
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences announced new two-year data for CRENESSITY® (crinecerfont) showing sustained improvements in cardiometabolic outcomes, bone health, and patient-reported quality of life in adults with classic congenital adrenal hyperplasia (CAH). These results, presented at ENDO 2026, demonstrate reductions in glucocorticoid dose, improvements in body weight, body composition, and insulin resistance, and favorable trends in bone mineral density. Patients also reported high satisfaction and improved emotional well-being and confidence in managing their condition with CRENESSITY.
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Neurocrine Biosciences announced clinical findings from a retrospective case series at ENDO 2026, showcasing the benefits of CRENESSITY® (crinecerfont) in pediatric and adult patients with classic congenital adrenal hyperplasia (CAH) due to 11β‑hydroxylase deficiency. The study revealed significant reductions in elevated adrenal hormone levels, including androstenedione, and decreased glucocorticoid doses in nearly all patients. These findings offer crucial initial insights into managing this rare CAH subtype, which was not previously studied in CRENESSITY clinical trials.
